Testing the feasibility of the QuitAid smoking cessation intervention in a randomized factorial design in an independent, rural community pharmacy.
Independent pharmacy
Medication therapy management
Nicotine replacement therapy
Rural health
Smoking cessation
Journal
Pilot and feasibility studies
ISSN: 2055-5784
Titre abrégé: Pilot Feasibility Stud
Pays: England
ID NLM: 101676536
Informations de publication
Date de publication:
26 Feb 2024
26 Feb 2024
Historique:
received:
22
05
2023
accepted:
14
02
2024
medline:
27
2
2024
pubmed:
27
2
2024
entrez:
26
2
2024
Statut:
epublish
Résumé
Adult smoking rates in the USA are highest in economically depressed rural Appalachia. Pharmacist-delivered tobacco cessation support that incorporates medication therapy management (such as the QuitAid intervention) is a promising approach to address this need. Twenty-four adult smokers recruited between September and November 2021 through an independent pharmacy in rural Appalachia were randomized in a non-blinded 2 × 2 × 2 factorial design to (1) pharmacist delivered QuitAid intervention (yes vs. no); (2) combination nicotine replacement therapy (NRT) gum + NRT patch (vs. NRT patch); and/or (3) 8 weeks of NRT (vs. standard 4 weeks). Participants received 4 weeks of NRT patch in addition to the components to which they were assigned. Participants completed baseline and 3-month follow-up assessments. Primary outcomes were feasibility of recruitment and randomization, retention, treatment adherence, and fidelity. Participants were recruited in 7 weeks primarily through a referral process, commonly referred to as ask-advise-connect (61%). Participants were on average 52.4 years old, 29.2% were male and the majority were white (91.6%) and Non-Hispanic (91.7%). There was a high level of adherence to the interventions, with 85% of QuitAid sessions completed, 83.3% of the patch used, and 54.5% of gum used. Participants reported a high level of satisfaction with the program, and there was a high level of retention (92%). This demonstration pilot randomized controlled study indicates that an ask-advise-connect model for connecting rural smokers to smoking cessation support and providing QuitAid for smoking cessation is feasible and acceptable among rural Appalachian smokers and independent pharmacists. Further investigation into the efficacy of a pharmacist-delivered approach for smoking cessation is needed. The trial was retrospectively registered at ClinicalTrials.gov. Trial #: NCT05649241.
Sections du résumé
BACKGROUND
BACKGROUND
Adult smoking rates in the USA are highest in economically depressed rural Appalachia. Pharmacist-delivered tobacco cessation support that incorporates medication therapy management (such as the QuitAid intervention) is a promising approach to address this need.
METHODS
METHODS
Twenty-four adult smokers recruited between September and November 2021 through an independent pharmacy in rural Appalachia were randomized in a non-blinded 2 × 2 × 2 factorial design to (1) pharmacist delivered QuitAid intervention (yes vs. no); (2) combination nicotine replacement therapy (NRT) gum + NRT patch (vs. NRT patch); and/or (3) 8 weeks of NRT (vs. standard 4 weeks). Participants received 4 weeks of NRT patch in addition to the components to which they were assigned. Participants completed baseline and 3-month follow-up assessments. Primary outcomes were feasibility of recruitment and randomization, retention, treatment adherence, and fidelity.
RESULTS
RESULTS
Participants were recruited in 7 weeks primarily through a referral process, commonly referred to as ask-advise-connect (61%). Participants were on average 52.4 years old, 29.2% were male and the majority were white (91.6%) and Non-Hispanic (91.7%). There was a high level of adherence to the interventions, with 85% of QuitAid sessions completed, 83.3% of the patch used, and 54.5% of gum used. Participants reported a high level of satisfaction with the program, and there was a high level of retention (92%).
CONCLUSIONS
CONCLUSIONS
This demonstration pilot randomized controlled study indicates that an ask-advise-connect model for connecting rural smokers to smoking cessation support and providing QuitAid for smoking cessation is feasible and acceptable among rural Appalachian smokers and independent pharmacists. Further investigation into the efficacy of a pharmacist-delivered approach for smoking cessation is needed.
TRIAL REGISTRATION
BACKGROUND
The trial was retrospectively registered at ClinicalTrials.gov. Trial #: NCT05649241.
Identifiants
pubmed: 38409089
doi: 10.1186/s40814-024-01465-9
pii: 10.1186/s40814-024-01465-9
doi:
Banques de données
ClinicalTrials.gov
['NCT05649241']
Types de publication
Journal Article
Langues
eng
Pagination
41Subventions
Organisme : NCI NIH HHS
ID : R01CA267963
Pays : United States
Organisme : NCI NIH HHS
ID : P30CA044579
Pays : United States
Informations de copyright
© 2024. The Author(s).
Références
Marshall J, Alcalde G. Creating a culture of health in Appalachia. In: The first report in a series of exploring health disparities in Appalachia. 2018.
American Lung Association. Trends in cigarette smoking rates. 2021. Accessed 10 Sept 2022.
Creamer MR, Wang TW, Babb S, et al. Tobacco product use and cessation indicators among adults — United States, 2018. MMWR. 2019;68:1013–9. https://doi.org/10.15585/mmwr.mm6845a2 .
doi: 10.15585/mmwr.mm6845a2
pubmed: 31725711
pmcid: 6855510
Virginia Department of Health. Health behavior by health district. Richmond: Virginia Department of Health; 2021.
Pilehvari A, You W, Krukowski RA, Little MA. Examining smoking prevalence disparities in Virginia counties by rurality, Appalachian status, and social vulnerability, 2011–2019. Am J Public Health. 2023;113(7):811–4. https://doi.org/10.2105/ajph.2023.307298 .
doi: 10.2105/ajph.2023.307298
pubmed: 37141556
Northridge ME, Vallone D, Xiao H, et al. The importance of location for tobacco cessation: rural-urban disparities in quit success in underserved West Virginia Counties. J Rural Health. 2008;24(2):106–15. https://doi.org/10.1111/j.1748-0361.2008.00146.x .
doi: 10.1111/j.1748-0361.2008.00146.x
pubmed: 18397443
Hodge FS, Fredericks L, Kipnis P. Patient and smoking patterns in northern California American Indian clinics: urban and rural contrasts. Cancer. 1996;78(7 Suppl):1623–8.
doi: 10.1002/(SICI)1097-0142(19961001)78:7+<1623::AID-CNCR19>3.0.CO;2-7
pubmed: 8839583
Hutcheson TD, Greiner KA, Ellerbeck EF, Jeffries SK, Mussulman LM, Casey GN. Understanding smoking cessation in rural communities. J Rural Health. 2008;24(2):116–24. https://doi.org/10.1111/j.1748-0361.2008.00147.x .
doi: 10.1111/j.1748-0361.2008.00147.x
pubmed: 18397444
Kruger TM, Howell BM, Haney A, Davis RE, Fields N, Schoenberg NE. Perceptions of smoking cessation programs in rural Appalachia. Am J Health Behav. 2012;36(3):373–84. https://doi.org/10.5993/AJHB.36.3.8 .
doi: 10.5993/AJHB.36.3.8
pubmed: 22370438
pmcid: 3297972
Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146. https://doi.org/10.1002/14651858.CD000146.pub4 .
doi: 10.1002/14651858.CD000146.pub4
pubmed: 23152200
Little MA, Krukowski RA, Wiseman KP, et al. Determining the feasibility of a pharmacistdelivered smoking cessation intervention for rural smokers in partnership with independent community pharmacies. Tob Prev Cessation. 2022;8(Supplement):A31. https://doi.org/10.18332/tpc/150967 .
Tobacco Use and Dependence Guideline Panel. Treating tobacco use and dependence: 2008 update. US Department of Health and Human Services. http://www.ncbi.nlm.nih.gov/books/NBK63952/ . Accessed 22 Nov 2013.
North American Quitline Consortium. Results from the 2019 NAQC Annual Survey of Quitlines. 2019.
Mersha AG, Gould GS, Bovill M, Eftekhari P. Barriers and facilitators of adherence to nicotine replacement therapy: a systematic review and analysis using the capability, opportunity, motivation, and behaviour (COM-B) model. Int J Environ Res Public Health. 2020;17(23):8895. https://doi.org/10.3390/ijerph17238895 .
doi: 10.3390/ijerph17238895
pubmed: 33265956
pmcid: 7731205
Hammond D, McDonald PW, Fong GT, Borland R. Do smokers know how to quit? Knowledge and perceived effectiveness of cessation assistance as predictors of cessation behaviour. Addiction. 2004;99(8):1042–8. https://doi.org/10.1111/j.1360-0443.2004.00754.x .
doi: 10.1111/j.1360-0443.2004.00754.x
pubmed: 15265101
Lindson N, Chepkin SC, Ye W, Fanshawe TR, Bullen C, Hartmann‐Boyce J. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2019;(4). https://doi.org/10.1002/14651858.CD013308 .
Raupach T, Brown J, Herbec A, Brose L, West R. A systematic review of studies assessing the association between adherence to smoking cessation medication and treatment success. Addiction. 2014;109(1):35–43. https://doi.org/10.1111/add.12319 .
doi: 10.1111/add.12319
pubmed: 23919621
Hollands GJ, Naughton F, Farley A, Lindson N, Aveyard P. Interventions to increase adherence to medications for tobacco dependence. Cochrane Database Syst Rev. 2019;(8). https://doi.org/10.1002/14651858.CD009164.pub3 .
National Association of Chain Drug Stores. NACDS: face-to-face with community pharmacies. www.nacds.org/pdfs/about/rximpact-leavebehind.pdf . Accessed 8 Nov 2021.
Prokhorov AV, Hudmon KS, Marani S, et al. Engaging physicians and pharmacists in providing smoking cessation counseling. Arch Intern Med. 2010;170(18):1640–6. https://doi.org/10.1001/archinternmed.2010.344 .
doi: 10.1001/archinternmed.2010.344
pubmed: 20937922
pmcid: 5089700
American Public Health Association. The role of the pharmacist in public health. Policy Statements and Advocacy. www.apha.org/policies-and-advocacy/public-health-policy-statements/policy-database/2014/07/07/13/05/the-role-of-the-pharmacist-in-public-health . 2006.
Casserlie LM, DiPietroMager NA. Pharmacists’ perceptions of advancing public health priorities through medication therapy management. Pharm Pract (Granada). 2016;14(3):792. https://doi.org/10.18549/PharmPract.2016.03.792 .
doi: 10.18549/PharmPract.2016.03.792
pubmed: 27785167
Doucette WR, Kreling DH, Schommer JC, Gaither CA, Mott DA, Pedersen CA. Evaluation of community pharmacy service mix: evidence from the 2004 National Pharmacist Workforce Study. J Am Pharm Assoc. 2006;46(3):348–55. https://doi.org/10.1331/154434506777069471 .
doi: 10.1331/154434506777069471
Ismail N. Prescribing authority for pharmacists: rules and regulations by state. GoodRx. www.goodrx.com/hcp/pharmacists/prescriber-authority-for-pharmacists . Accessed 5 Mar 2021.
Carson-Chahhoud KV, Livingstone-Banks J, Sharrad KJ, et al. Community pharmacy personnel interventions for smoking cessation. Cochrane Database Syst Rev. 2019;2019(10). https://doi.org/10.1002/14651858.CD003698.pub3 .
Patwardhan PD, Chewning BA. Ask, advise and refer: hypothesis generation to promote a brief tobacco-cessation intervention in community pharmacies. Int J Pharm Pract. 2009;17(4):221–9. https://doi.org/10.1211/ijpp/17.04.0005 .
doi: 10.1211/ijpp/17.04.0005
pubmed: 20161528
pmcid: 2801921
Burns A. Medication therapy management in pharmacy practice: core elements of an MTM service model (version 2.0). J Am Pharm Assoc. 2008;48(3):341–53. https://doi.org/10.1331/JAPhA.2008.08514 .
doi: 10.1331/JAPhA.2008.08514
Viswanathan M, Kahwati LC, Golin CE, et al. Medication therapy management interventions in outpatient settings: a systematic review and meta-analysis. JAMA Intern Med. 2015;175(1):76. https://doi.org/10.1001/jamainternmed.2014.5841 .
doi: 10.1001/jamainternmed.2014.5841
pubmed: 25401788
Pellegrino AN, Martin MT, Tilton JJ, Touchette DR. Medication therapy management services: definitions and outcomes. Drugs. 2009;69(4):393–406. https://doi.org/10.2165/00003495-200969040-00001 .
doi: 10.2165/00003495-200969040-00001
pubmed: 19323584
Bunting BA, Cranor CW. The Asheville project: long-term clinical, humanistic, and economic outcomes of a community-based medication therapy management program for asthma. J Am Pharm Assoc. 2006;46(2):133–47. https://doi.org/10.1331/154434506776180658 .
doi: 10.1331/154434506776180658
Bunting BA, Smith BH, Sutherland SE. The Asheville Project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia. J Am Pharm Assoc. 2008;48(1):23–31. https://doi.org/10.1331/JAPhA.2008.07140 .
doi: 10.1331/JAPhA.2008.07140
Lounsbery JL, Green CG, Bennett MS, Pedersen CA. Evaluation of pharmacists’ barriers to the implementation of medication therapy management services. J Am Pharm Assoc. 2009;49(1):51–8. https://doi.org/10.1331/JAPhA.2009.07158 .
doi: 10.1331/JAPhA.2009.07158
Moczygemba LR, Barner JC, Brown CM, et al. Patient satisfaction with a pharmacist-provided telephone medication therapy management program. Res Soc Adm Pharm. 2010;6(2):143–54. https://doi.org/10.1016/j.sapharm.2010.03.005 .
doi: 10.1016/j.sapharm.2010.03.005
Fiore MC. Treating tobacco use and dependence: 2008 update: clinical practice guideline. Rockville: DIANE Publishing; 2008.
Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42. https://doi.org/10.1186/1748-5908-6-42 .
doi: 10.1186/1748-5908-6-42
pubmed: 21513547
pmcid: 3096582
Fucito LM, Toll BA, Salovey P, O’Malley SS. Beliefs and attitudes about bupropion: implications for medication adherence and smoking cessation treatment. Psychol Addict Behav. 2009;23(2):373.
doi: 10.1037/a0015695
pubmed: 19586156
pmcid: 3094849
Mooney ME, Sayre SL, Hokanson PS, Stotts AL, Schmitz JM. Adding MEMS feedback to behavioral smoking cessation therapy increases compliance with bupropion: a replication and extension study. Addict Behav. 2007;32(4):875–80.
doi: 10.1016/j.addbeh.2006.06.022
pubmed: 16839698
Schmitz JM, Sayre SL, Stotts AL, Rothfleisch J, Mooney ME. Medication compliance during a smoking cessation clinical trial: a brief intervention using MEMS feedback. J Behav Med. 2005;28(2):139–47.
doi: 10.1007/s10865-005-3663-4
pubmed: 15957569
Schlam TR, Fiore MC, Smith SS, et al. Comparative effectiveness of intervention components for producing long-term abstinence from smoking: a factorial screening experiment. Addiction. 2016;111(1):142–55. https://doi.org/10.1111/add.13153 .
doi: 10.1111/add.13153
pubmed: 26581819
Horne R, Chapman SC, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLoS One. 2013;8(12):e80633. https://doi.org/10.1371/journal.pone.0080633 .
doi: 10.1371/journal.pone.0080633
pubmed: 24312488
pmcid: 3846635
Motivational interviewing in brief consultations. https://new-learning.bmj.com/course/10051582 . Accessed 4 Nov 2021.
CITI Program. IRB-HSR researcher basic course. citiprogram.org. Accessed 14 Dec 2021.
Hall MA, Camacho F, Dugan E, Balkrishnan R. Trust in the medical profession: conceptual and measurement issues. Health Serv Res. 2002;37(5):1419–39. https://doi.org/10.1111/1475-6773.01070 .
doi: 10.1111/1475-6773.01070
pubmed: 12479504
pmcid: 1464022
Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991;86(9):1119–27.
doi: 10.1111/j.1360-0443.1991.tb01879.x
pubmed: 1932883
Leon AC, Davis LL, Kraemer HC. The role and interpretation of pilot studies in clinical research. J Psychiatr Res. 2011;45(5):626–9. https://doi.org/10.1016/j.jpsychires.2010.10.008 .
doi: 10.1016/j.jpsychires.2010.10.008
pubmed: 21035130
Cramer H. Learning to fly: conceptions and misconceptions, uses and misuses of pilot studies in clinical research. J Altern Complement Med. 2021;27(7):531–4. https://doi.org/10.1089/acm.2021.0197 .
doi: 10.1089/acm.2021.0197
pubmed: 34255537
Teresi JA, Yu X, Stewart AL, Hays RD. Guidelines for designing and evaluating feasibility pilot studies. Med Care. 2022;60(1):95–103. https://doi.org/10.1097/mlr.0000000000001664 .
doi: 10.1097/mlr.0000000000001664
pubmed: 34812790
pmcid: 8849521
Salgado García FI, Derefinko KJ, Bursac Z, et al. Fit & quit: an efficacy trial of two behavioral post-cessation weight gain interventions. Contemp Clin Trials. 2019;76:31–40. https://doi.org/10.1016/j.cct.2018.11.009 .
doi: 10.1016/j.cct.2018.11.009
pubmed: 30445176
Little MA, Ebbert JO, Bursac Z, et al. Enhancing the efficacy of a smoking quit line in the military: study rationale, design and methods of the Freedom quit line. Contemp Clin Trials. 2017;59:51–6. https://doi.org/10.1016/j.cct.2017.04.011 .
doi: 10.1016/j.cct.2017.04.011
pubmed: 28479219
pmcid: 5551396
Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res. 2003;5(1):13–25. https://doi.org/10.1093/ntr/5.1.13 .
doi: 10.1093/ntr/5.1.13
pubmed: 12745503
Benowitz NL, Bernert JT, Caraballo RS, Holiday DB, Wang J. Optimal serum cotinine levels for distinguishing cigarette smokers and nonsmokers within different racial/ethnic groups in the United States between 1999 and 2004. Am J Epidemiol. 2009;169(2):236–48. https://doi.org/10.1093/aje/kwn301 .
doi: 10.1093/aje/kwn301
pubmed: 19019851
Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat. 2005;4(4):287–91. https://doi.org/10.1002/pst.185 .
doi: 10.1002/pst.185
Billingham SA, Whitehead AL, Julious SA. An audit of sample sizes for pilot and feasibility trials being undertaken in the United Kingdom registered in the United Kingdom Clinical Research Network database. BMC Med Res Methodol. 2013;13:104. https://doi.org/10.1186/1471-2288-13-104 .
doi: 10.1186/1471-2288-13-104
pubmed: 23961782
pmcid: 3765378
Dent LA, Harris KJ, Noonan CW. Tobacco interventions delivered by pharmacists: a summary and systematic review. Pharmacotherapy. 2007;27(7):1040–51.
doi: 10.1592/phco.27.7.1040
pubmed: 17594210
Schlam TR, Cook JW, Baker TB, et al. Can we increase smokers’ adherence to nicotine replacement therapy and does this help them quit? Psychopharmacology. 2018;235(7):2065–75. https://doi.org/10.1007/s00213-018-4903-y .
doi: 10.1007/s00213-018-4903-y
pubmed: 29696311
pmcid: 6141024
Smith SS, Keller PA, Kobinsky KH, et al. Enhancing tobacco quitline effectiveness: identifying a superior pharmacotherapy adjuvant. Nicotine Tob Res. 2013;15(3):718–28. https://doi.org/10.1093/ntr/nts186 .
doi: 10.1093/ntr/nts186
pubmed: 22992296
Stead LF, Hartmann-Boyce J, Perera R, Lancaster T. Telephone counselling for smoking cessation. Cochrane Database Syst Rev. 2013;8:Cd002850. https://doi.org/10.1002/14651858.CD002850.pub3 .
doi: 10.1002/14651858.CD002850.pub3
West R, Hajek P, Nilsson F, Foulds J, May S, Meadows A. Individual differences in preferences for and responses to four nicotine replacement products. Psychopharmacology. 2001;153(2):225–30. https://doi.org/10.1007/s002130000577 .
doi: 10.1007/s002130000577
pubmed: 11205423
Centers for Disease Control and Prevention. How to use nicotine gum. Centers for Disease Control and Prevention. Accessed 19 Nov 2023.
Little MA, Porter KJ, Pebley K, et al. Evaluating the feasibility of pharmacist-facilitated tobacco cessation interventions in independent community pharmacies in rural Appalachia. J Am Pharm Assoc. 2022. https://doi.org/10.1016/j.japh.2022.06.015 .
Pharmacy CE Courses Office of Continuing Education. CE tobacco cessation. Purdue University. https://ce.pharmacy.purdue.edu/courses/course/index.php?categoryid=20 . Accessed 14 Oct 2021.
Schoenberg NE, Huang B, Seshadri S, Tucker TC. Trends in cigarette smoking and obesity in Appalachian Kentucky. South Med J. 2015;108(3):170–7.
doi: 10.14423/SMJ.0000000000000245
pubmed: 25772051
Cardarelli K, Westneat S, Dunfee M, May B, Schoenberg N, Browning S. Persistent disparities in smoking among rural Appalachians: evidence from the Mountain Air Project. BMC Public Health. 2021;21(1):270. https://doi.org/10.1186/s12889-021-10334-6 .
doi: 10.1186/s12889-021-10334-6
pubmed: 33530976
pmcid: 7856720
Jayakumar N, Chaiton M, Zhang B, Selby P, Schwartz R. Sex differences in use of smoking cessation services and resources: a real-world study. Tob Use Insights. 2020;13:1179173x20901500. https://doi.org/10.1177/1179173x20901500 .
doi: 10.1177/1179173x20901500
pubmed: 32030067
pmcid: 6977215